文献速递免疫规划传染病防控与疫情报告

威斯康星州儿童接种1-4剂百日咳疫苗后品牌特异性百日咳发病率(2010-2014)

Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014.
PubMed 文献 · Vaccine · 2020-09-11

本研究为前瞻性观察性队列研究,采用病例-队列设计,在威斯康星州2010-2014年<60月龄接种≤4剂百日咳疫苗的儿童中,通过随机电话调查估计人口特征和疫苗接种情况,比较仅接种Pentacel疫苗者与其他单一品牌疫苗接种者的百日咳发病率。共发现1195例百日咳病例,估计 surveillance population 累计1,133,403人年。结果显示两组百日咳发病率相似(98.9/100,000 vs 96.2/100,000),调整后率比为0.99(90%CI 0.89-1.12);延迟接种者百日咳风险增加66%(90%CI 39-96%)。

要点

  • 接种Pentacel与其他品牌百日咳疫苗的儿童百日咳发病率无显著差异。
  • 延迟接种百日咳疫苗使百日咳风险增加66%(90%CI 39-96%)。
  • 随机电话调查可有效描述队列人群,支持难以实施的疫苗上市后研究。

核心结论

  • 新许可的Pentacel疫苗与其他可用百日咳疫苗在预防百日咳方面未发现保护差异。
  • 延迟接种百日咳疫苗显著增加百日咳风险。

研究设计与样本

  • 前瞻性观察性研究,采用病例-队列设计,2010-2014年在威斯康星州开展。
  • 研究对象为<60月龄、接种≤4剂百日咳疫苗的威斯康星州居民(监测人群)。
  • 通过持续随机电话调查估计监测人群的特征和百日咳疫苗接种情况。

主要发现

  • 共识别1195例百日咳病例。
  • 监测人群估计累计1,133,403人年,其中Group 1占39%,Group 2占41%,Group 3占20%。
  • Group 1(仅接种Pentacel)百日咳发病率为98.9/100,000,Group 2(接种其他单一品牌)为96.2/100,000。
  • 未调整率比为1.03(90%CI 0.92-1.15),调整后率比为0.99(90%CI 0.89-1.12)。
  • 有≥1剂延迟接种者百日咳风险增加66%(90%CI 39-96%)。

临床怎么用

  • 应按时接种百日咳疫苗,避免延迟接种以降低百日咳风险。
  • 不同品牌百日咳疫苗的保护效果未见显著差异,疫苗选择可基于其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acellular pertussis vaccines were initially licensed based on placebo-controlled efficacy trials, but such trials are no longer ethical. The effectiveness of current pertussis vaccines among properly vaccinated children <5 years is so high that a randomized trial is infeasible. Fluctuations in pertussis incidence and characteristics of the US vaccine marketplace make selection of suitable controls for a case-control study problematic. To satisfy an FDA requirement to evaluate rates of pertussis following licensure of Pentacel® vaccine, we used a case-cohort study design with a novel method for characterizing the cohort population. METHODS: This prospective, observational study was conducted in Wisconsin from 2010 to 2014 among Wisconsin residents <60 months of age who received ≤four doses of pertussis vaccine (surveillance population). Cases were identified by the Wisconsin Division of Public Health. Characteristics and pertussis vaccinations of the surveillance population were estimated by ongoing random telephonic survey. The primary objective was to determine rates of pertussis disease among those who received only Pentacel vaccine (Group 1) vs those who received a single brand of vaccine other than Pentacel vaccine (Group 2). RESULTS: 1195 pertussis cases were identified. It was estimated that the surveillance population accrued a total of 1,133,403 person-years (Group 1, 39%; Group 2, 41%; Group 3 [those not in Group 1 or Group 2], 20%). Pertussis rates were similar in Group 1 (98.9/100,000) and Group 2 (96.2/100,000); rate ratios were 1.03 (unadjusted; 90% CI, 0.92-1.15) and 0.99 (adjusted; 90% CI, 0.89-1.12). Persons with one or more delayed vaccinations had a 66% higher risk of pertussis (90% CI, 39-96%). DISCUSSION: Pertussis protection was not found to differ for recipients of the newly licensed vs other available pertussis vaccines. Delayed vaccination substantially increased risk of pertussis. Sample survey methodology was able to characterize the study cohort and enable an otherwise-infeasible study. Clinical Trial Registry number: ClinicalTrials.gov, NCT01129362.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Conway JH, Davis JP, Eickhoff JC, et al. Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014. Vaccine. 2020. PMID: 32921507. doi:10.1016/j.vaccine.2020.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。